Results 241 to 250 of about 590,194 (288)

A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix^® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age. [PDF]

Infect Dis Ther
Koski S, Martinon-Torres F, Rämet M, Zolotas L, Newton R, Maansson R, Cutler M, Peyrani P, Findlow J, Balmer P, Jodar L, Gruber WC, Anderson AS, Beeslaar J.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California.

Clinical Infectious Diseases, 2022
BACKGROUND Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased gonorrhea incidence. Although a gonorrhea-specific vaccine does not exist, N. gonorrhoeae
K. Bruxvoort, J. Lewnard, Lie-Hong Chen, H. Tseng, Jennifer J. Chang, J. Marrazzo, L. Qian   +6 more
semanticscholar   +1 more source

Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents.

Clinical Infectious Diseases, 2021
BACKGROUND From 2017 a state-wide cluster randomized trial was conducted in South Australia to assess the impact of the meningococcal B vaccine 4CMenB on pharyngeal N. meningitidis carriage in adolescents.
M. McMillan, Bing Wang, A. Koehler, Thomas R Sullivan, H. Marshall   +4 more
semanticscholar   +1 more source

Meningococcal Vaccines

Infectious Disease Clinics of North America, 2001
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y ...
N E, Rosenstein, M, Fischer, J W, Tappero   +2 more
openaire   +2 more sources

First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England.

Clinical Infectious Diseases, 2020
BACKGROUND 4CMenB is a protein-based meningococcal group B vaccine but the vaccine antigens may also be present on non-group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunisation programme, alongside an ...
S. Ladhani, H. Campbell, N. Andrews, S. Parikh, Joanne White, M. Edelstein, S. Clark, J. Lucidarme, R. Borrow, M. Ramsay   +9 more
semanticscholar   +1 more source

Meningococcal conjugate vaccines

Expert Opinion on Pharmacotherapy, 2004
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis in the US, Europe and in many other parts of the world, including parts of sub-Saharan Africa (known as the African 'meningitis belt'). There are > 500000 cases of meningococcal disease annually with an estimated death toll of 135000 worldwide.
David S. Stephens, Shanta M. Zimmer
openaire   +3 more sources